NEURO & NOOTROPIC
Cerebrolysin
Neuropeptide preparation derived from porcine brain protein. Studied in neurotrophic literature.
Bundle & save
Free shipment protection · Overnight shipping available · Ships from our Naples, FL facility
Free shipping
on orders over $150
Damage protection
replacement guarantee
Secure checkout
256-bit SSL
Certificate of Analysis
Third-party tested · ISO/IEC 17025 accredited
99%
purity
✓ Passed full QC panel
- Variant
- Cerebrolysin · 60 mg
- Lot #
- AML-2026-0504
- Labeled
- 60 mg
- Tested
- 2026-04-12
Full QC panel
- Purity (HPLC)
- 99%
- Net Peptide Content
- Pass
- Identity (HPLC-MS)
- Confirmed
- Heavy Metals (ICP-MS)
- Not detected
- Sterility
- No growth
- Endotoxin (LAL)
- Within limits
Purity, lot and tested date are per-lot; remaining QC rows are representative — exact values on the CoA.
Compound Information
Chemical and structural properties
Chemical identity verified via NIH PubChem · biological targets characterized from the peer-reviewed literature.
Molecular profile
Structure
- CAS Number
- —
- Molecular Formula
- —
- Molecular Weight
- 0 g/mol
- Sequence
- (peptide mixture; see COA)
- Type
- Research peptide
Biological targets
Interactions
- Primary target
- Neurotrophic-factor signaling (BDNF / GDNF / NGF-like activity)
- Pathway
- Neurotrophin pathways; anti-apoptotic; neuroplasticity
- Mechanism
- Standardized mixture of low-molecular-weight neuropeptides and amino acids
- Research area
- Neuroprotection, stroke and dementia research
Physical properties
Handling & Storage
- Appearance
- Clear amber peptide solution (porcine-derived)
- Solubility
- Aqueous; supplied and handled as a solution
- Storage
- 2-8 deg C, protect from light
- Country of origin
- USA
Sources & References
Peer-reviewed research
Indexed in NIH PubMed. Provided for research context; not a claim of clinical outcome.
MEDICINAL RESEARCH REVIEWS
Modulation of neurotrophic factors in the treatment of dementia, stroke and TBI: Effects of Cerebrolysin
2023 · PMID 37052231
Rejdak K et al.
View Source ↗CNS & NEUROLOGICAL DISORDERS DRUG TARGETS
Cerebrolysin, a mixture of neurotrophic factors induces marked neuroprotection in spinal cord injury following intoxication of engineered nanoparticles from metals
2012 · PMID 22229324
Menon PK et al.
View Source ↗DRUGS OF TODAY (BARCELONA, SPAIN : 1998)
The pharmacology of neurotrophic treatment with Cerebrolysin: brain protection and repair to counteract pathologies of acute and chronic neurological disorders
2012 · PMID 22514792
Masliah E et al.
View Source ↗THE COCHRANE DATABASE OF SYSTEMATIC REVIEWS
Cerebrolysin for acute ischaemic stroke
2017 · PMID 28430363
Ziganshina LE et al.
View Source ↗EXPERT REVIEW OF CLINICAL PHARMACOLOGY
The effectiveness of cerebrolysin, a multi-modal neurotrophic factor, for treatment of post-covid-19 persistent olfactory, gustatory and trigeminal chemosensory dysfunctions: a randomized clinical trial
2023 · PMID 37950370
Hamed SA et al.
View Source ↗
⚠ Important research notice
PRODUCTS ARE INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly prohibited by law. Products should only be handled by licensed, qualified professionals. Products sold are not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food, or cosmetic.
All the research peptides you need, with the peace of mind at your fingertips.
Research updates from Aminologix
Catalog updates, new research compounds, and quality-documentation news. For researchers and labs. No spam, unsubscribe anytime.